• FDA cleared AbbVie’s JUVMO (tavapadon) tablets for adults with Parkinson’s disease, marking the first selective D1/D5 receptor agonist in the US.
• Label allows once-daily dosing as monotherapy or alongside levodopa to manage motor symptoms across the disease course.
• AbbVie expects US patient availability in October 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609280800PR_NEWS_USPR_____CG55171) on September 28, 2026, and is solely responsible for the information contained therein.